Edition:
United States

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

297.60DKK
24 May 2017
Change (% chg)

kr.3.20 (+1.09%)
Prev Close
kr.294.40
Open
kr.294.30
Day's High
kr.297.80
Day's Low
kr.293.90
Volume
409,572
Avg. Vol
614,347
52-wk High
kr.334.60
52-wk Low
kr.220.70

Summary

Name Age Since Current Position

Joergen Buhl Rasmussen

62 2017 Chairman of the Board

Peder Holk Nielsen

60 2013 President, Chief Executive Officer

Agnete Raaschou-Nielsen

60 2017 Vice Chairman of the Board

Benny Loft

51 2013 Executive Vice President, Corporate Functions; Chief Financial Officer

Thomas Videbaek

56 2016 Chief Operating Officer; Executive Vice President, Research, Innovation & Supply

Andrew Fordyce

54 2016 Executive Vice President, Food & Beverages

Anders Lund

44 2016 Executive Vice President, Household Care & Technical

Tina Sejersgaard Fanoe

48 2016 Executive Vice President, Agriculture & Bioenergy

Lena Bech Halskov

50 2013 Director, Employee Representative

Lars Green

50 2014 Director

Anders Hentze Knudsen

58 2013 Director, Employee Representative

Lars Koeppler

55 2010 Director, Employee Representative

Kasim Kutay

2017 Director

Kim Stratton

2017 Director

Heinz-Juergen Bertram

58 2015 Independent Director

Mathias Uhlen

63 2007 Independent Director

Martin Riise

2016 Head of Investor Relations

Biographies

Name Description

Joergen Buhl Rasmussen

Mr. Joergen Buhl Rasmussen has been Chairman of the Board of Directors of Novozymes A/S since February 22, 2017. He has previously been Independent Vice Chairman of the Board since February 24, 2016. He has been Independent Member of the Board of Directors at the Company from March 1, 2011 until February 24, 2016. He is also Member of the Board of Directors at IFC Europe A/S and Human Practice Foundation as well as Member of Advisory Board of Axcel. He is also Chairman of F. Uhrenholt A/S. He has competencies in acquisitions, international business and management, specifically within sales, marketing, and branding. He is also Adjunct Professor at Copenhagen Business School.

Peder Holk Nielsen

Mr. Peder Holk Nielsen has been President and Chief Executive Officer (CEO) of Novozymes A/S since April 1, 2013. Previously, he served as Executive Vice President of Enzyme Business at the Company from 2007 and as Executive Vice President of Business Operations from 2000. He is also Member of the Board of Directors at Hempel A/S and LEO Pharma A/S. He joined Novo A/S in 1984 as Product Manager of Enzymes Division. In 1987, he became Head of the New Business Development Group. He took over as Vice President in Research & Development in the Enzyme Process Division in 1990. In 1995, he joined the management team of the enzyme business in Novo Nordisk A/S initially as head of Development and Quality Management, and from 1999 he led Sales and Marketing in the enzymes business. He held this position until the demerger of Novozymes from Novo Nordisk. With the creation of Novozymes in 2000, he continued running the operational side of the business as Executive Vice President, responsible for Sales, Marketing and Supply Chain activities. In 2007, he assumed responsibility for all of Enzyme Business, including production, procurement, development and quality management. He holds a Master of Science degree in Chemical Engineering from the Technical University of Denmark (Danmarks Tekniske Universitet) from 1981, and a Doctorate of Philosophy degree from the Institute of Chemical Engineering at the Technical University of Denmark from 1984. He also holds a Bachelor of Commerce degree in International Business Management from the Copenhagen Business School from 1985.

Agnete Raaschou-Nielsen

Ms. Agnete Raaschou-Nielsen has been Vice Chairman of the Board of Directors of Novozymes A/S since February 22, 2017. She has previously been Independent Director since February 24, 2016. Previously, she was Independent Vice Chairman of the Board of Directors at the Company from February 26, 2014 until February 24, 2016. She has been Independent Member of the Board of Directors of the Company since March 1, 2011. She is also Member of the Company's Audit Committee. She is also Chairman of the Board of Directors at Brdr. Hartmann A/S, Arkil Holding A/S, and Chairman of the Board of Directors at Danske Invest, three other UCITS funds and two AIF funds. She is also Vice Chairman of Dalhoff Larsen & Horneman A/S and Solar A/S. She acts as Member of the Boards of Directors at Danske Invest Management A/S and Aktieselskabet Schouw & Co. She is also Member of the Audit Committee of Aktieselskabet Schouw & Co. and Solar A/S. She has competencies in business development and acquisitions, macroeconomics and intellectual property rights.

Benny Loft

Mr. Benny D. Loft has been Executive Vice President, Corporate Functions and Chief Financial Officer at Novozymes A/S since April 1, 2013. Before that, he has serves as Executive Vice President and Chief Financial Officer at Novozymes A/S. Prior to joining Novo Nordisk in 1998, he spent a decade with Price Waterhouse, where he served as Consultant and Auditor for Novo Nordisk, among others. He joined Novo Nordisk in 1998 as Director for Consolidated Accounts, Group Taxation and Tax Planning, and Stocks and Production Economy. He was involved in the demerger of Novo Nordisk and Novozymes A/S. During the same period, he was responsible for building Novozymes A/S' finance department. He has served as Vice President for Finance at Novozymes, and has also worked within acquisitions and negotiations. He currently serves as Member of the Boards of Directors of New Xellia Group A/S and DONG Energy A/S. He is also Chairman of the Audit Committee at DONG Energy A/S and New Xellia Group A/S. He holds a Master of Science degree in Accounting, Tax and Auditing from the Copenhagen Business School. He became State-Authorized Public Accountant in 1996.

Thomas Videbaek

Dr. Thomas Videbaek has been Chief Operating Officer and Executive Vice President, Research, Innovation & Supply at Novozymes A/S since February 8, 2016. Previously, he was Executive Vice President of Business Development at the Company from April 1, 2013 until February 8, 2016. Before that, he served as Executive Vice President of BioBusiness at the Company since September 2007. He is also Member of the Board of Directors of Evolva SA and Vice Chairman of Albumedix A/S. He joined Novo Nordisk as Chemist in 1988 in Technical Service, Textile Enzymes. From 1990 to 1991, he served as Business Development Manager for Textile in the United States, and was later appointed Global Marketing Manager for Textile. In 1995, he became Global Marketing Director for Starch, and in 1996, he also assumed responsibility for Food and Feed enzymes, and was appointed Director for Strategic Marketing, Food and Feed enzymes, where he became responsible for analyzing market possibilities and developing marketing strategies and plans for the food and feed industries. In 1998, he was appointed General Manager for Novozymes Switzerland, as well as Vice President for Cereal Food and Beverage Marketing. In 2003, he became Vice President for Supply Chain Operations with responsibility for establishing a global organization in charge of the supply chain at Novozymes. In 2005, he became Vice President for Sales and Customer Solutions with responsibility for the global Sales and Customer Solutions organization. He holds a Master of Science degree in Chemical Engineering degree from the Technical University of Denmark's (Danmarks Tekniske Universitet) Department of Nutrition and Biochemistry in Copenhagen from 1986, and a Doctorate of Philosophy degree from the Technical University of Denmark from 1990. He also holds a Bachelor of Commerce degree in International Business from the Copenhagen Business School from 1992.

Andrew Fordyce

Mr. Andrew Fordyce has been Executive Vice President, Food & Beverages at Novozymes A/S since February 8, 2016. Previously, he was Executive Vice President of Business Operations at the Company from April 1, 2013 until February 8, 2016. He was previously Vice President of Sales and Customer Solutions. Since joining the Company in 1993, he has held several positions in commercial operations, research and development and production in Denmark, Switzerland and the United States. He holds a Doctorate of Philosophy degree in Chemical Engineering from the University of Texas at Austin.

Anders Lund

Mr. Anders Lund has been Executive Vice President, Household Care & Technical at Novozymes A/S since February 8, 2016. Formerly, he was Vice President of Sales at the Company. He holds a Master of Science in Economics from Aarhus University, Denmark. He started his career with the company in 1999 and has held various leadership positions across Marketing, Sales and as Head of Supply Chain.

Tina Sejersgaard Fanoe

Ms. Tina Sejersgaard Fanoe has been Executive Vice President, Agriculture & Bioenergy at Novozymes A/S since February 8, 2016. She is also Board Member of DLF Seeds & Science and Professional Packaging Systems. Previously, she was Vice President of Sales at the Company. She holds a Master of Science in Chemical Engineering from the Technical University of Denmark, as well as a bachelor’s degree in philosophy and education from Copenhagen University, Denmark. She started her career with the company in 1993 and has held various positions within R&D, Marketing, Business Development and Sales.

Lena Bech Halskov

Ms. Lena Bech Halskov has been Employee Representative on the Board of Directors of Novozymes A/S since February 28, 2013. She is Safety Adviser.

Lars Green

Mr. Lars Hall Green has been Member of the Board of Directors of Novozymes A/S since February 26, 2014. He is Chairman of the Company's Audit Committee. He is also Senior Vice President, Finance and Operations of Novo Nordisk Inc. (US). He has international experience from managing global biotech and biopharma companies, and financial and accounting expertise.

Anders Hentze Knudsen

Mr. Anders Hentze Knudsen has been Employee Representative on the Board of Directors at Novozymes A/S since February 28, 2013. He is Senior Operator.

Lars Koeppler

Mr. Lars Bo Koeppler has served as Employee Representative on the Board of Directors at Novozymes A/S since December 1, 2010. He is Technician. Previously, he was Member of the Company's Board of Directors until 2004. He is Member of the Board of Novo Nordisk Foundation.

Kasim Kutay

Kim Stratton

Heinz-Juergen Bertram

Dr. Heinz-Juergen Bertram has served as Independent Member of the Board of Directors of Novozymes A/S since February 25, 2015. He also serves as Chief Executive Officer of Symrise AG and Member of the Board of Nord/LB Holzminden and Deutsche Bank Hannover. He is also Member of the Nomination Committee of Probi AB and was Board Member of Rockwool A/S until February 2016. He has experience in international business, management and in converting research and biotechnology into commercial products and solutions.

Mathias Uhlen

Mr. Mathias Uhlen has been Independent Member of the Board of Directors at Novozymes A/S since 2007. He is Professor at the Royal Institute of Technology (Kungliga Tekniska Hogskolan - KTH) in Stockholm, Sweden and the Technical University of Denmark (Danmarks Tekniske Universitet, DTU). He is also Chairman of the Board of Directors at Antibodypedia AB and Atlas Antibodies AB, as well as Vice Chairman of the Board of Directors at Affibody AB. He acts as Member of the Board of Directors at Alligator AB, Woodheads AB and Bure Equity AB. He has experience in research and biotechnology.

Martin Riise

Basic Compensation